Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

2018 Global Multiple Sclerosis Market Insights, Epidemiology and Forecasts to 2027 - Trends and Opportunities -

Research and Markets
Posted on: 22 Feb 18

The "Multiple Sclerosis - Market Insights, Epidemiology and Market Forecasts to 2027" report has been added to's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Multiple Sclerosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

According to research, the global market of Multiple Sclerosis was estimated to be USD 21.25 billion in 2016.

The prevalent population of Multiple Sclerosis was estimated to be 1.98 Million [7MM] in 2016. United States accounts for the highest MS Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. In United States, the peak prevalence has been observed in patients aged 45-49 years in both female and male participants.

The drugs marketed for the treatment of mainly include disease-modifying therapies (DMT) - Copaxone, Tecfidera, Gilenya, Tysabri, Avonex, Aubagio, Lemtrada, Ocrevus, Rebif , Betaseron, Extavia, Plegridy, Fampyra, and Zinbryta . Detailed chapters for all of these drugs, along with the upcoming therapies i.e., [Siponimod (Novartis), Ponesimod (Johnson and Johnson), Ozanimod (Celgene), Ofatumumab (Novartis), Ublituximab (TG Therapeutics), ALKS 8700 (Alkermes Plc), and Mavenclad (Merck KgaA)] have been covered in the report.

Companies Mentioned:

  • AB Science
  • Acorda Therapeutics
  • Bayer Healthcare
  • Biogen
  • Celgene Corporation
  • Genentech
  • Genzyme
  • Johnson & Johnson
  • MedDay Pharma
  • Merck KGA
  • Novartis
  • Teva Pharmaceutical
  • TG Therapeutics

Key Topics Covered:

1. Report Introduction

2. Multiple Sclerosis Market Overview at a Glance

3. Disease Background and Overview: Multiple Sclerosis (MS)

4. Epidemiology and Patient Population

5. Epidemiology of Multiple Sclerosis

6. United States

7. Germany

8. France

9. Italy

10. Spain

11. United Kingdom

12. Japan

13. Treatment Algorithm

14. Unmet Needs

15. Marketed Drugs

16. Betaferon: Bayer Healthcare

17. Rebif: Merck KGA

18. Copaxone: Teva Pharmaceutical

19. Avonex: Biogen Idec. Limited

20. Tysabri: Biogen Idec. Limited

21. Fampyra/Ampyra: Acorda Therapeutics/Biogen Idec Ltd.

22. Gilenya: Novartis

23. Aubagio: Genzyme

24. Tecfidera: Biogen Idec Ltd.

25. Plegridy: Biogen Idec Ltd.

26. Lemtrada: Genzyme

27. Zinbryta: Biogen Idec

28. Ocrevus: Genentech

29. Mavenclad: Merck

30. Emerging Therapies

31. Global Market Size of Multiple Sclerosis (MS)

32. United States

33. EU5

34. EU-5 Broken Down by Countries

35. Japan

36. Trends observed in MS therapies Cost in United States

37. Generic Competition in MS Market

38. Market Drivers

39. Market Barriers

40. Appendix

41. Report Methodology

For more information about this report visit

View source version on

Business Wire

Last updated on: 22/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.